HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
CompletedNCT05304767

Long-term KarXT safety research for schizophrenia symptoms

About this titleRead the official source — NCT05304767
Medication studyAges 18–65Multiple countries
The study in practice

Understand this study

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Listed locations
Phoenix and 93 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: March 7, 2022
Recruitment status
Completed
Enrollment listed in the registry
290
Sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Sponsor type
Biotech company
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States, Bulgaria, Japan, ...
Age range
From 18 Years to 65 Years
Official registry ID
NCT05304767
Official title
Show the full official title

An Open-label Extension Study to Assess the Long-term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Phoenix, United States · Little Rock, United States · Anaheim, United States

69 more locations
  • Bellflower, United States
  • Cerritos, United States
  • Culver City, United States
  • Garden Grove, United States
  • La Habra, United States
  • Lafayette, United States
  • Lemon Grove, United States
  • Oceanside, United States
  • Orange, United States
  • Pico Rivera, United States
  • Riverside, United States
  • Stanford, United States
  • Torrance, United States
  • Coral Gables, United States
  • Hialeah, United States
  • Lauderhill, United States
  • Miami, United States
  • Miami Lakes, United States
  • Pembroke Pines, United States
  • Tampa, United States
  • Atlanta, United States
  • Decatur, United States
  • Marietta, United States
  • Chicago, United States
  • Gaithersburg, United States
  • Boston, United States
  • St Louis, United States
  • Omaha, United States
  • Las Vegas, United States
  • Berlin, United States
  • New York, United States
  • Rochester, United States
  • Staten Island, United States
  • Hickory, United States
  • Independence, United States
  • Eugene, United States
  • Austin, United States
  • Fort Worth, United States
  • Houston, United States
  • Irving, United States
  • Richardson, United States
  • Richmond, United States
  • Rutland, United States
  • Bellevue, United States
  • Sofia, Bulgaria
  • Kazanlak, Bulgaria
  • Cherven Bryag, Bulgaria
  • Dupnitsa, Bulgaria
  • Kardzhali, Bulgaria
  • Novi Iskar, Bulgaria
  • Pleven, Bulgaria
  • Plovdiv, Bulgaria
  • Razgrad, Bulgaria
  • Sliven, Bulgaria
  • Targovishte, Bulgaria
  • Varna, Bulgaria
  • Vratsa, Bulgaria
  • Toyoake-shi, Japan
  • Fukuoka, Japan
  • Shirakawa-shi, Japan
  • Karatsu-shi, Japan
  • Meguro-ku, Japan
  • Setagaya-ku, Japan
  • Shinjuku-ku, Japan
  • Belgrade, Serbia
  • Gornja Toponica, Serbia
  • Kovin, Serbia
  • Kragujevac, Serbia
  • Novi Kneževac, Serbia
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Karuna Therapeutics, Inc., a Bristol Myers Squibb company.

Did this study involve medication?

Yes. The study involved medication, including Xanomeline and Trospium Chloride Capsules.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies